Hosted on MSN
Chemed outlines 2025 growth strategies amid strong VITAS momentum and Roto-Rooter recovery
Kevin McNamara, CEO of Chemed, highlighted robust performance in VITAS operations, with a 7.3% year-over-year increase in admissions to 18,139 and a 13.1% growth in average daily census (ADC) to ...
Chemed’s CHE Roto-Rooter business has been registering robust performance over the past few quarters. A good solvency position buoys optimism. The company currently carries a Zacks Rank #2 (Buy). Over ...
VITAS Net Revenue: $391.4 million, an increase of 17.3% year-over-year. VITAS Admissions: 16,775, a 6.3% increase from the prior year. Average Daily Census (ADC) for VITAS: 21,785 patients, a 15.5% ...
installation, repair and replacement needs including: sewers and drains, faucets, sinks, toilets, showers & tubs, waterlines, pipework, disposers, dishwashers, water heaters and septic tanks.
Lexie is a former Staff Writer at Forbes Home and has over 6 years of professional experience as a writer and editor in the home improvement space. She's previously worked at sites such as HomeAdvisor ...
Zacks.com on MSN
Should Investors Hold Chemed Stock in Their Portfolio Now?
Chemed Corporation CHE is well-poised to grow in the coming quarters due to strong operational growth in the VITAS arm. Roto-Rooter maintains its core competitive edge in a challenging operational ...
VITAS Net Revenue: $407.7 million in Q3 2025, a 4.2% increase from the prior year. Roto-Rooter Revenue Increase: 1.1% in Q3 2025 compared to Q3 2024. VITAS Adjusted EBITDA: $70.4 million, a 3.8% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results